Pulmonx Corp (LUNG) · Oct 27, 2026 · Earnings
Beat — Revenue $22.84M vs ~$21.93M consensus; EPS $(0.19) vs ~(0.26) consensus
Pulmonx earnings beat Q3 revenue and EPS expectations, with U.S. growth and lower costs offsetting the unfinished China restart.
Pulmonx is a commercial-stage medical-device company rebuilding adoption of its Zephyr lung valve, with management trying to restart U.S. growth, sharpen its sales organization, and resume China shipments after renewing its registration certificate. Its core products target severe emphysema and COPD patients who remain symptomatic despite medical treatment.
The quarter cleared expectations on both revenue and loss. Revenue reached $22.8 million, up 6% year over year, versus published consensus of roughly $21.93 million; GAAP loss per share was $0.19 versus consensus near $0.26. That is a real beat, not merely a cleaner presentation of an in-line quarter. The EPS comparison is especially favorable because the loss narrowed despite higher interest expense and a larger share count.
| Metric | Q3 2026 | Q3 2025 / consensus | Read |
|---|---|---|---|
| Revenue | $22.835M (Financial Highlights) | $21.502M prior year; ~$21.93M consensus | +6.2% YoY; above consensus |
| GAAP EPS | $(0.19) (Income Statement) | $(0.34) prior year; ~(0.26) consensus | Better than expected |
| Gross margin | 76% (Financial Highlights) | 75% prior year | Expanded 1 point |
| Operating expenses | $24.889M (Income Statement) | $30.445M prior year | Down 18% |
| Adjusted EBITDA | $(3.528)M (Adjusted EBITDA reconciliation) | $(8.223)M prior year | Loss narrowed materially |
| Cash and equivalents | $52.690M (Balance Sheet) | $69.751M at Dec. 31, 2025 | Liquidity remains pressured |
The commercial recovery is becoming visible, but it is not broad-based yet. U.S. revenue grew 7% in the quarter, while international revenue grew 5%; excluding China, international revenue rose 9%. That supports management’s claim that the sales-force and commercial restructuring are beginning to work. But China still produced no revenue in the quarter, so the headline growth is coming from the existing U.S. and non-China international business rather than a full global recovery. 〔0〕
The cost reset is doing more work than the top line. Quarterly operating expenses fell to $24.9 million from $30.4 million, and adjusted EBITDA losses narrowed to $3.5 million from $8.2 million. Management also cut full-year operating-expense guidance to $108 million-$109 million from the prior $109 million-$111 million range, while reducing expected cash burn to approximately $22 million from approximately $23 million. This improves runway, but the company still ended September with $52.7 million of cash and $37.7 million of long-term debt, so the business remains dependent on continued execution rather than self-funded profitability.
The beat is meaningful, but the recovery is still early. Nine-month revenue remains down 2.5% year over year, including a 1.3% decline in the United States; the quarter’s return to growth is therefore a reversal of recent weakness, not yet proof of a sustained acceleration. The market had already been expecting a third-quarter return to growth after management’s second-quarter comments, which makes the upside mainly a matter of execution and magnitude rather than a surprise in direction.
Bottom line: This is a genuine earnings beat that advances Pulmonx’s turnaround story: U.S. growth has resumed, expenses are falling, and China provides potential upside once shipments restart. The result matters, but the company still needs several quarters of growth to prove the reset is durable rather than one good quarter.
China commercial restart and Q4 results
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!